Dupilumab in the treatment of severe non-control broncial asthma — economic aspects
Severe non-control Bronchial Asthma (BA) is a sufficient social problem with decreasing of quality of life, high index of disability and death. New biological drug — dupilumab — would improve the situation.Materials and methods. Markov’s model has been used for efficacy comparison of dupilumab and o...
Main Authors: | A. S. Salasyuk, M. Yu. Frolov, I. N. Barykina |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2019-10-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/448 |
Similar Items
-
Modeling of the impact of biological drugs in the economic burden of severe asthma
by: S. K. Zyryanov, et al.
Published: (2020-01-01) -
Experience of using dupilumab in the treatment of severe asthma
by: G. L. Ignatova, et al.
Published: (2020-09-01) -
Severe bronchial asthma patient care organization in various regions of the Russian Federation. From endotypes and phenotypes of bronchial asthma to personalized choice of therapy
by: S. N. Avdeev, et al.
Published: (2020-02-01) -
Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid
by: S. Morteza Seyed Jafari, et al.
Published: (2021-01-01) -
The Role of Dupilumab in Severe Asthma
by: Fabio Luigi Massimo Ricciardolo, et al.
Published: (2021-08-01)